Status:
ACTIVE_NOT_RECRUITING
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Kidney Disease With High Proteinuria
Eligibility:
All Genders
18-95 years
Phase:
PHASE3
Brief Summary
This is a Phase III, randomised, multicentre, double-blinded study to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with...
Eligibility Criteria
Inclusion
- Participant must be ≥ 18 years of age and of legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the informed consent.
- Diagnosis of CKD, defined as eGFR ≥ 20 and \< 90 mL/min/1.73 m2 and UACR \> 700 mg/g (\> 79 mg/mmol) or UPCR \> 1000 mg/g (\> 113 mg/mmoL).
- All female participants must have a negative serum pregnancy test result at screening.
- Female participants must be either
- not of child-bearing potential or
- women of child bearing potential (WOCBP) using at least one highly effective birth control method for at least 3 months prior to first dose of study intervention
- Capable of giving signed informed consent
- Provision of signed informed consent prior to any study specific procedure.
- Provision of electronic informed consent prior to completion of the optional Study Participant Feedback Questionnaire (SPFQ).
- Provision of signed and dated written Optional Genomics Initiative Research Information and Consent Form prior to collection of samples for optional genomics imitative research that supports the Genomic Initiative.
- Receiving RAASi therapy (ACEi or ARB), and for the patient maximum tolerated labelled daily dose, that has been stable for at least 4 weeks.
Exclusion
- Participants with NYHA class III or class IV Congestive HF at the time of enrolment.
- Participants hospitalised for HF during the last 6 month prior to screening.
- Evidence of rales or jugular venous distention on physical examination.
- Participants with type 1 diabetes mellitus.
- History of any life-threatening ventricular dysrhythmia (continuous or paroxysmal).
- Blood pressure above 160 mmHg systolic.
- Blood pressure below 90 mmHg systolic.
- Participants hospitalised for heart disease or cardiac procedures or for COVID-19 during the last 3 months prior to screening.
- History of solid organ transplantation or bone marrow transplant.
- History or ongoing allergy/hypersensitivity, as judged by the Investigator, to SGLT2i therapy (eg, dapagliflozin, canagliflozin, empagliflozin or other SGLT2 inhibitors) or Endothelin Receptor Antagonists (eg, ambrisentan, atrasentan, bosentan, or other).
- Any condition with a life expectancy of less than 2 years based on investigator´s clinical judgment.
- Malignancy within the past 5 years. Exceptions to this criterion include non-melanoma skin cancer and curatively treated cervical carcinoma in situ.
- Significant liver disease as judged by the investigator or severe hepatic impairment with AST or ALT \> 3 × ULN; or total bilirubin \> 2 × ULN at time of screening. An isolated increase in bilirubin in participants with known Gilbert's syndrome is not a reason for exclusion.
- Known blood-borne diseases.
- Clinically significant, unstable, or uncontrolled medical condition as assessed by the Investigator.
- Participants on renal replacement therapy or previous kidney transplant.
- Known history of drug or alcohol abuse within 12 months of screening.
- Participants on treatment with strong or moderate CYP3A4 inducer.
- Participants on systemic immunosuppression therapy other than stable maintenance therapy defined as prednisone 10 mg/day (or equivalent) or less, aziothioprine 100 mg/day or less; MMF 1000 mg/day or less for at least 3 months prior to Visit 1. Inhaled, nasal or dermatological steroids are also allowed.
- Participants treated or expecting to be treated with tolvaptan, any other ERAs, or budesonide (where used to treat IBD or IgAN).
- Participation in another clinical study with a study intervention administered in the last 3 months.
Key Trial Info
Start Date :
November 7 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 22 2027
Estimated Enrollment :
1835 Patients enrolled
Trial Details
Trial ID
NCT06087835
Start Date
November 7 2023
End Date
January 22 2027
Last Update
December 19 2025
Active Locations (296)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Huntsville, Alabama, United States, 35805
2
Research Site
Sun City West, Arizona, United States, 85375
3
Research Site
Bakersfield, California, United States, 93309
4
Research Site
Huntington Park, California, United States, 90255